NCT06207552View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2029

Conditions
Fabry Disease
Interventions
GENETIC

BBM-F101 injection

The dose of BBM-F101 injection will be calculated according to the participant's weight with single intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER